Revisiting the Design of Phase III Clinical Trials of Antimalarial Drugs for Uncomplicated Plasmodium falciparum Malaria

Steffen Borrmann and colleagues discuss appropriate endpoints and their measurement during phase III trials of new antimalarial drugs.

Detalles Bibliográficos
Autores principales: Borrmann, Steffen, Peto, Tim, Snow, Robert W, Gutteridge, Win, White, Nicholas J
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2008
Materias:
Policy Forum
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2586344/
https://www.ncbi.nlm.nih.gov/pubmed/19018658
http://dx.doi.org/10.1371/journal.pmed.0050227
Descripción
Sumario:Steffen Borrmann and colleagues discuss appropriate endpoints and their measurement during phase III trials of new antimalarial drugs.

Ejemplares similares